CRISPR Therapeutics Ownership

CRSP
 Stock
  

USD 78.90  1.44  1.86%   

Some institutional investors establish a significant position in stocks such as CRISPR Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of CRISPR Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Continue to Trending Equities.
  
As of 12th of August 2022, Preferred Dividends Income Statement Impact is likely to drop to about 666.6 K. As of 12th of August 2022, Issuance Purchase of Equity Shares is likely to grow to about 284.5 M, while Weighted Average Shares is likely to drop about 62.1 M.
CRISPR Therapeutics holds a total of seventy-six million five hundred thirty thousand outstanding shares. Over half of CRISPR Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Thus, these institutions are subject to different rules and regulation than regular investors in CRISPR Therapeutics. Please watch out for any change in the institutional holdings of CRISPR Therapeutics as this could mean something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

CRISPR Stock Ownership Analysis

About 64.0% of the company shares are held by institutions such as insurance companies. The book value of CRISPR Therapeutics was currently reported as 32.86. The company has Price/Earnings To Growth (PEG) ratio of 0.04. CRISPR Therapeutics recorded earning per share (EPS) of 5.26. The entity had not issued any dividends in recent years. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people. For more info on CRISPR Therapeutics AG please contact Rodger Novak at 41 41 561 32 77 or go to https://www.crisprtx.com.
Besides selling stocks to institutional investors, CRISPR Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different CRISPR Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align CRISPR Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

CRISPR Therapeutics Quarterly Share Based Compensation

24.85 Million

Only 1.33% of CRISPR Therapeutics AG are currently held by insiders. Unlike CRISPR Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against CRISPR Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

CRISPR Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. CRISPR Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that CRISPR Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial CRISPR Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
13th of June 2022
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
20th of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

CRISPR Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CRISPR Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CRISPR Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CRISPR Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samarth Kulkarni over a week ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 16667 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over a month ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3
Fleming Harold Edward over two months ago via Macroaxis 
Acquisition by Fleming Harold Edward of 12000 shares of CRISPR Therapeutics subject to Rule 16b-3
Morrow Phuong Khanh over two months ago via Macroaxis 
Acquisition by Morrow Phuong Khanh of 90000 shares of CRISPR Therapeutics subject to Rule 16b-3
Klein Lawrence Otto over three months ago via Macroaxis 
Exercise or conversion by Klein Lawrence Otto of 3000 shares of CRISPR Therapeutics subject to Rule 16b-3
Smith Brendan over three months ago via Macroaxis 
Acquisition by Smith Brendan of 15300 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over six months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 17750 shares of CRISPR Therapeutics subject to Rule 16b-3
Klein Lawrence Otto over six months ago via Macroaxis 
Exercise or conversion by Klein Lawrence Otto of 26667 shares of CRISPR Therapeutics subject to Rule 16b-3
James Kasinger over six months ago via Macroaxis 
Exercise or conversion by James Kasinger of 7342 shares of CRISPR Therapeutics subject to Rule 16b-3
Smith Brendan over six months ago via Macroaxis 
Acquisition by Smith Brendan of 90000 shares of CRISPR Therapeutics subject to Rule 16b-3
Klein Lawrence Otto over six months ago via Macroaxis 
Payment of 10000 shares by Klein Lawrence Otto of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over six months ago via Macroaxis 
Payment of 787 shares by Samarth Kulkarni of CRISPR Therapeutics subject to Rule 16b-3

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Center Now

   

Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.63CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr
0.83BCTXBriaCell Therapeutics Fiscal Year End 27th of October 2022 PairCorr
0.87BEAMBeam Therapeutics Buyout TrendPairCorr

Moving against CRISPR Therapeutics

0.87INMInmed Pharmaceuticals Fiscal Year End 23rd of September 2022 PairCorr
0.73KZIAKazia Therapeutics Fiscal Year End 6th of October 2022 PairCorr
0.69CASICasi Pharmaceuticals Earnings Call  TodayPairCorr
0.67INVAInnoviva Normal TradingPairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.